26 August 2020

ReiThera’s COVID-19 Vaccine Candidate Enters Phase 1 Clinical Study with First Healthy Volunteer Dosed in Italy

The Phase 1 study is being conducted in Italy at the Lazzaro Spallanzani National Institute for Infectious Diseases (INMI) in Rome and at the GB Rossi University Hospital in Verona.
07 August 2020

EU support for Italian biotech’s red blood cell technology to treat rare diseases

European Investiment Bank signs €30 million agreement supporting EryDel’s red blood cell (RBC) innovation strategy
14 July 2020

Bioeconomy in Europe, the 6th Report by Assobiotec and Intesa Sanpaolo

The pandemic caused by the SARS-COV2 virus has made it more evident that the models of economic development need to be rethought with a greater focus on sustainability and respect for the environment. A look at the new report on Bioeconomy in Europe
26 May 2020

Axxam enters into Drug Discovery Collaboration with Vivozon for CNS Indications

Axxam S.p.A. announces a collaboration with Vivozon Inc. with the aim to support Vivozon in the development of innovative small molecule drugs for the treatment of patients with unmet CNS medical needs.
01 May 2020

CORONAVIRUS - Axxam supports drug discovery efforts to identify novel inhibitors for SARS-CoV-2

A commitment to support the identification of antiviral therapies to treat the severe acute respiratory syndrome COVID-19, caused by the Coronavirus SARS-CoV-2.
19 April 2020

Newron Receives Third Tranche from Financing Agreement with European Investment Bank (EIB)

Tranche 3 consists of EUR 7.5 million and will primarily be used to support the Company’s development programs in diseases of the central nervous system.


Where to find us

20149 Milan
Via Giovanni da Procida, 11
Show map 
Tel. +39 02.34565.1
Fax. +39 02.34565.310
Segreteria Assobiotec
Tel. 02 34565.256/341